{
    "2019-12-06": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Health Care Stocks Gurus Broadly Own",
                "features": {
                    "keywords": [
                        "health care",
                        "stocks",
                        "gurus"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Here's why Oregon rejected Johnson & Johnson's pelvic mesh settlement offer",
                "features": {
                    "keywords": [
                        "Oregon",
                        "rejected",
                        "Johnson & Johnson",
                        "pelvic mesh",
                        "settlement"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Pharma Stock Roundup: FDA Updates for RHHBY, AZN, MRK, No Asbestos in Talc Says JNJ",
                "features": {
                    "keywords": [
                        "pharma",
                        "FDA",
                        "updates",
                        "RHHBY",
                        "AZN",
                        "MRK",
                        "JNJ",
                        "asbestos",
                        "talc"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-25",
                "original_text": "Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "NDA",
                        "Fostemsavir",
                        "pre-treated",
                        "HIV"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}